Pharmaceutical Procurement

Pharmaceutical procurement occupies a complex intersection between public procurement law and pharmaceutical regulation. Medicines are regulated products subject to marketing authorisation, pharmacovigilance requirements, and pricing controls that exist entirely outside the procurement framework. At the same time, health systems spend enormous sums on medicines and apply procurement disciplines to achieve value. Understanding how these two systems interact is essential for pharmaceutical suppliers navigating European public health markets.

What is Pharmaceutical Procurement?

Pharmaceutical procurement across Europe takes several distinct forms depending on the product type and the purchasing body.

Hospital medicines procurement. Hospitals and hospital trusts procure branded and generic medicines through tenders, framework agreements, and catalogue purchasing. EU Directive 2014/24/EU applies to above-threshold hospital medicines contracts, and the competitive process typically involves both price and non-price criteria. Generic medicines are often purchased through price-only tenders where multiple suppliers qualify and the lowest compliant price wins.

National pricing and reimbursement. For many medicines, national health technology assessment (HTA) bodies (such as NICE in the UK, HAS in France, or G-BA in Germany) negotiate or set reimbursement prices centrally. In these cases, individual hospital procurement is downstream of a national pricing decision. EU HTA coordination under Regulation 2021/2282 is reshaping how joint European assessments feed into national reimbursement, with joint clinical assessments applying across EU member states.

Joint EU procurement. The EU has operated joint procurement for vaccines and pandemic countermeasures since 2013. The emergency procurement exercises conducted during COVID-19 demonstrated both the potential and the coordination challenges of European joint medicines purchasing. The EU Solidarity mechanism for critical medicines is expanding and provides a route for coordinated procurement across member states.

Biosimilars and advanced therapies. Procurement of biosimilar medicines (where original biological medicines come off patent) is a growing area. EU procurement policy encourages biosimilar adoption through competitive tendering. Advanced therapy medicinal products (ATMPs) such as gene and cell therapies present new procurement challenges given their extremely high unit cost and individualised manufacturing processes.

In the UK, NHS England's Commercial Medicines Unit and pharmacy procurement frameworks manage hospital medicines. The NHS procurement framework applies alongside NICE guidance on value and cost-effectiveness.

Why it matters for bidders

Pharmaceutical companies bidding for European public procurement contracts must navigate both procurement law and pharmaceutical regulation simultaneously. A product must hold a valid marketing authorisation for the relevant territory before it can be included in a tender. EU-based suppliers need EMA or national competent authority authorisation; UK-based suppliers need MHRA authorisation.

Pricing strategy is particularly sensitive: public tenders create price reference points that can affect parallel import risks and cross-country reimbursement negotiations. Suppliers competing in multiple EU member states should model the downstream pricing implications of bids in individual national tenders. Healthcare supply chain considerations also apply, including cold chain management, shelf-life requirements, and security of supply as evaluated in major pharmaceutical framework agreements.

Example

A European generic medicines company wishes to supply a hospital antibiotic to NHS trusts in England. It ensures its product holds MHRA marketing authorisation and is included in the relevant NHS Supply Chain medicines catalogue. When an NHS trust runs a mini-competition under the medicines framework, it submits the lowest compliant price for the required specification. Because generics procurement is heavily price-driven for off-patent molecules, its competitive cost base from EU manufacturing is the decisive factor.

Frequently Asked Questions

Does EU procurement law apply to all medicines purchased by public bodies?

Yes, where contracts are above the relevant threshold (221,000 euros for central government bodies). Many large hospital medicines frameworks are well above threshold and are openly tendered on the TED portal. Below-threshold purchases may be made through national or local purchasing arrangements without OJEU publication, though national transparency rules may still apply.

Can a contracting authority limit pharmaceutical tenders to EU-authorised products?

Yes. Requiring a valid marketing authorisation from the EMA or a national medicines authority is a legitimate qualification criterion, not discriminatory. Products without authorisation cannot legally be supplied and may be excluded on that basis without challenge.

What is the difference between a biosimilar tender and a standard generic tender?

Generic medicines are chemically identical to the originator product and are interchangeable at the pharmacy level. Biosimilars are highly similar but not identical biological medicines; substitution requires clinical oversight. Hospital procurement of biosimilars therefore involves more clinical engagement and may include therapeutic equivalence requirements or specialist input from clinical pharmacists in the specification.